Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial
    Fakhouri, Fadi
    Hourmant, Maryvonne
    Campistol, Josep M.
    Cataland, Spero R.
    Espinosa, Mario
    Gaber, A. Osama
    Menne, Jan
    Minetti, Enrico E.
    Provot, Francois
    Rondeau, Eric
    Ruggenenti, Piero
    Weekers, Laurent E.
    Ogawa, Masayo
    Bedrosian, Camille L.
    Legendre, Christophe M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (01) : 84 - 93
  • [42] Centchroman as First-line Treatment for Mastalgia: Results of an Open-label, Single-arm Trial
    Rathi, Jalaj
    Chawla, Inderjit
    Singh, Karnail
    Chawla, Arjun
    BREAST JOURNAL, 2016, 22 (04): : 407 - 412
  • [43] Opicapone OASIS study in Parkinson's: design of an open-label, single-arm, pilot trial
    Costa, R.
    Trenkwalder, C.
    Ferreira, J.
    Magalhaes, D.
    Rocha, J.
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 628 - 628
  • [44] Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
    Marron, Thomas U.
    Fiel, Maria Isabel
    Hamon, Pauline
    Fiaschi, Nathalie
    Kim, Edward
    Ward, Stephen C.
    Zhao, Zhen
    Kim, Joel
    Kennedy, Paul
    Gunasekaran, Ganesh
    Tabrizian, Parissa
    Doroshow, Deborah
    Legg, Meredith
    Hammad, Ashley
    Magen, Assaf
    Kamphorst, Alice O.
    Shareef, Muhammed
    Gupta, Namita T.
    Deering, Raquel
    Wang, Wei
    Wang, Fang
    Thanigaimani, Pradeep
    Mani, Jayakumar
    Troncoso, Leanna
    Tabachnikova, Alexandra
    Chang, Christie
    Akturk, Guray
    Buckup, Mark
    Hamel, Steven
    Ioannou, Giorgio
    Hennequin, Clotilde
    Jamal, Hajra
    Brown, Haley
    Bonaccorso, Antoinette
    Labow, Daniel
    Sarpel, Umut
    Rosenbloom, Talia
    Sung, Max W.
    Kou, Baijun
    Li, Siyu
    Jankovic, Vladimir
    James, Nicola
    Ham, Sara C.
    Cheung, Hung Kam
    Sims, Jennifer S.
    Miller, Elizabeth
    Bhardwaj, Nina
    Thurston, Gavin
    Lowy, Israel
    Gnjatic, Sacha
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 219 - 229
  • [45] Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
    Marty, Francisco M.
    Ostrosky-Zeichner, Luis
    Cornely, Oliver A.
    Mullane, Kathleen M.
    Perfect, John R.
    Thompson, George R., III
    Alangaden, George J.
    Brown, Janice M.
    Fredricks, David N.
    Heinz, Werner J.
    Herbrecht, Raoul
    Klimko, Nikolai
    Klyasova, Galina
    Maertens, Johan A.
    Melinkeri, Sameer R.
    Oren, Ilana
    Pappas, Peter G.
    Racil, Zdenek
    Rahav, Galia
    Santos, Rodrigo
    Schwartz, Stefan
    Vehreschild, J. Janne
    Young, Jo-Anne H.
    Chetchotisakd, Ploenchan
    Jaruratanasirikul, Sutep
    Kanj, Souha S.
    Engelhardt, Marc
    Kaufh, Achim
    Ito, Masanori
    Lee, Misun
    Sasse, Carolyn
    Maher, Rochelle M.
    Zeiher, Bernhardt
    Vehreschild, Maria J. G. T.
    LANCET INFECTIOUS DISEASES, 2016, 16 (07): : 828 - 837
  • [46] Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine
    Watanabe, Hirohisa
    Hattori, Tatsuya
    Kume, Akito
    Misu, Kenichiro
    Ito, Takashi
    Koike, Yu
    Johnson, Todd A.
    Kamitsuji, Shigeo
    Kamatani, Naoyuki
    Sobue, Gen
    MEDICINE, 2020, 99 (35) : E21576
  • [47] Adjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial
    Mark J. Buchfuhrer
    Asim Roy
    Stephanye Rodriguez
    Jonathan D. Charlesworth
    BMC Neurology, 23
  • [48] Pharmacokinetics and safety of brivaracetam in neonates with repeated electroencephalographic seizures: A multicenter, open-label, single-arm study
    Pressler, Ronit
    Boylan, Geraldine
    Dempsey, Eugene
    Klotz, Kerstin Alexandra
    Krauwinkel, Walter
    Will, Edgar
    Morita, Diego
    Floricel, Florin
    Elshoff, Jan-Peer
    van den Anker, John
    EPILEPSIA OPEN, 2024, 9 (02) : 522 - 533
  • [49] Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study
    Tsuyoshi Matsumura
    Hiroya Hashimoto
    Masahiro Sekimizu
    Akiko M. Saito
    Yasufumi Motoyoshi
    Akinori Nakamura
    Satoshi Kuru
    Takayasu Fukudome
    Kazuhiko Segawa
    Toshiaki Takahashi
    Takuhisa Tamura
    Tetsuo Komori
    Chigusa Watanabe
    Masanori Asakura
    Koichi Kimura
    Yuko Iwata
    Orphanet Journal of Rare Diseases, 17
  • [50] Adjunctive tonic motor activation enables opioid reduction for refractory restless legs syndrome: a prospective, open-label, single-arm clinical trial
    Buchfuhrer, Mark J.
    Roy, Asim
    Rodriguez, Stephanye
    Charlesworth, Jonathan D.
    BMC NEUROLOGY, 2023, 23 (01)